Copper peptide · 5 min read

GHK-Cu: Research Guide

A tiny natural peptide that carries copper, popular in skin care and studied for wound healing and tissue repair.

Evidence
Early clinical
References
22 PubMed sources
Last reviewed
Status
Information only
Human evidence
CSmall human studies of skin creams and gels; almost no human data on injections.Small or early human studies, or trials of a closely related form (e.g. oral boosters, skin creams).
FDA status
Not approved · FDA safety concerns

Not approved as a medicine. FDA has flagged compounded injectable GHK-Cu as a possible safety risk; it is widely used in cosmetics.

Sport (WADA)
Conditional

Not named on the 2026 list, but the catch-all for unapproved substances may apply. Check with your anti-doping body.

My experience
6 out of 10

How well it has worked for me, from 1 to 10. One person's experience, not evidence, and not a recommendation or dosing advice.Read my experience →

Sources for these ratings are cited in the guide below, mainly in Legal status.

At a glance

Sequence
Gly-His-Lys (GHK), bound to a copper ion
Molecular weight
≈340 Da for GHK alone; ≈400 Da with copper bound
Formula
C14H24N6O4 (GHK, without copper)
Class
Naturally occurring copper-binding tripeptide
Also known as
Copper peptide · Copper tripeptide · Prezatide copper · Glycyl-L-histidyl-L-lysine

What is GHK-Cu?

GHK is one of the smallest peptides your body makes: just three amino acids, glycine, histidine, and lysine. It’s found naturally in blood, saliva, and urine, and the amount in your body declines with age [1]. Scientists first identified it in human blood in the 1970s [2], and soon found that it travels bound to copper [3]. That copper-carrying form is GHK-Cu, sometimes listed under the drug-style name prezatide copper [S1].

Here’s a neat detail: the same three-amino-acid sequence is built into collagen, the main protein in skin. Researchers think enzymes may release GHK from collagen at the site of a wound, where it can help with repair [4].

Today GHK-Cu is best known as a skin-care ingredient, widely used in anti-wrinkle creams and serums [5]. It’s also sold online as an injectable product, a use FDA has flagged over safety concerns [S2].

How might it work?

Lab studies suggest GHK-Cu acts like a coordinator for tissue repair:

  • Building collagen. Even tiny amounts stimulated skin cells called fibroblasts to make more collagen in the lab [4].
  • Clearing and rebuilding. Healthy repair means breaking down damaged tissue as well as building new tissue. GHK-Cu boosted both the enzymes that break down old tissue and the molecules that keep those enzymes in check [6].
  • Changing gene activity. Using a large database of how compounds affect genes, researchers found that GHK could reverse a gene-activity pattern linked to lung destruction in emphysema. In the lab, it also helped lung cells from people with COPD regain their normal function [7]. The team that discovered GHK reports that it can switch thousands of human genes up or down [1].

What has research found?

In animals

  • Wounds: In rats with wounds that had poor blood supply, a GHK-Cu gel shrank wounds by 65% over 13 days, compared with 28% in untreated rats, and reduced markers of inflammation [8]. In mice with burns, GHK-Cu packaged in tiny fat bubbles (liposomes) sped healing and boosted new blood vessel growth [9].
  • Not every study is positive: In rats whose skin had been damaged by radiation, a GHK-Cu gel made no difference to healing [10].
  • Lungs: In mice, GHK reduced lung scarring caused by a drug used to model pulmonary fibrosis [11].
  • Knee ligaments: In rats that had knee ligament surgery, GHK-Cu injected into the joint improved the repaired ligament at 6 weeks, but the benefit faded by 12 weeks after the injections stopped [12].

In people

  • Diabetic foot ulcers: In a placebo-controlled trial, a GHK-Cu gel helped diabetic foot ulcers close much more completely than a placebo gel (a median of 98.5% versus 60.8%). Treated ulcers were also far less likely to become infected (7% versus 34%) [13].
  • Leg ulcers: In a trial of 86 people with leg ulcers caused by poor circulation, a GHK-Cu cream worked no better than a placebo cream [14].
  • After laser skin treatment: In a small trial of 13 people, a GHK-Cu skin-care routine didn’t measurably reduce redness or wrinkles compared with a regular routine. But people using GHK-Cu were more satisfied with their skin [15].
  • Anti-aging skin care: GHK-Cu products are promoted to tighten skin and smooth fine lines [1], but a 2025 review found a “surprising absence” of clinical studies behind those claims [5]. A 2026 systematic review found just 2 randomized trials among 20 studies [16].
  • Injections: No published human trials have tested injected GHK-Cu, and FDA notes that human safety data are limited [S2]. A phase 2 wound-healing trial is now recruiting [17].

How strong is the evidence?

What we know so farWhat we still don’t know
Lab and animal studies consistently show effects on collagen, tissue repair, inflammation, and blood vessels [17]Whether those effects hold up in people, because clinical evidence is still sparse [17]
One placebo-controlled trial found a gel sped healing of diabetic foot ulcers [13]Whether skin creams deliver enough of it, since GHK-Cu doesn’t easily pass through the skin’s outer layer [18]
It’s a natural body peptide that declines with age [1]Whether injecting it is safe or effective [S2]
It’s widely used in cosmetics [5]The best formulation and dose [16]

A few more things to keep in mind:

  • Human results are mixed. One trial was strongly positive, while two others found no measurable benefit [13, 14, 15].
  • Not all “GHK-Cu” is the same. Products can differ in how much copper is actually bound and how stable they are, and studies rarely check [17].
  • Some of the boldest claims come from a single team. Many wide-ranging reviews are written by GHK’s discoverer, whose research team works at a skin-care company [19].
  • No proven use for injuries. A 2026 sports medicine review found no clinical data supporting GHK-Cu for muscle, tendon, or joint conditions [20].

Safety: what we know

  • On the skin: In lab tests, GHK-Cu didn’t irritate skin cells, unlike some other copper compounds. Researchers concluded it’s a gentler way to deliver copper to the skin [21].
  • Injections: FDA warns that compounded injectable GHK-Cu may trigger immune reactions because of clumping and impurities, and that there’s little human safety data [S2].
  • Loose copper: Researchers point out that products can contain different amounts of loose (“free”) copper, which matters for safety and is rarely measured [17].
  • Unregulated products: Injectable peptides sold directly to consumers operate largely outside regulatory oversight, and rigorous human safety data are scarce [22].
  • As a medicine: It hasn’t been proven or approved as a treatment for any condition. Researchers still call it promising but unproven [17].
  • Skin care: It’s widely sold as an ingredient in cosmetic anti-wrinkle products [5].
  • Injections: FDA has flagged compounded injectable GHK-Cu as a possible safety risk [S2].
  • Sports: GHK-Cu isn’t named on the World Anti-Doping Agency’s 2026 banned list. However, the list’s catch-all category bans substances not approved as medicines, so athletes should check with their anti-doping organization before using it [S3].

The bottom line

GHK-Cu is a fascinating little molecule. It’s natural, it declines with age, and in lab and animal studies it seems to coordinate many steps of tissue repair. A GHK-Cu gel sped the healing of diabetic foot ulcers in a controlled trial, and the skin-care industry has embraced it.

The human evidence, though, is still thin and mixed, and there’s almost nothing on injections. Well-designed trials using carefully defined products, like the wound-healing study now recruiting, will show whether the lab promise carries over to people.

References

Peer-reviewed sources indexed in PubMed, numbered in order of first citation. Study type is shown so you can judge how directly each source applies to humans.

  1. 1

    Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int, 2015:648108.

  2. 2

    Schlesinger DH, Pickart L, Thaler MM (1977). Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia, 33(3):324-5.

  3. 3

    Pickart L, Thaler MM (1980). Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol, 102(2):129-39.

  4. 4

    Maquart FX, Pickart L, Laurent M, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett, 238(2):343-6.

  5. 5

    Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 15:30071.

  6. 6

    Siméon A, Emonard H, Hornebeck W, et al. (2000). The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci, 67(18):2257-65.

  7. 7

    Campbell JD, McDonough JE, Zeskind JE, et al. (2012). A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med, 4(8):67.

  8. 8

    Canapp SO Jr, Farese JP, Schultz GS, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg, 32(6):515-23.

  9. 9

    Wang X, Liu B, Xu Q, et al. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen, 25(2):270-278.

  10. 10

    Parker NP, Ardeshirpour F, Schmechel SC, et al. (2013). Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngol Head Neck Surg, 149(3):384-9.

  11. 11

    Zhou XM, Wang GL, Wang XB, et al. (2017). GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition. Front Pharmacol, 8:904.

  12. 12

    Fu SC, Cheuk YC, Chiu WY, et al. (2015). Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res, 33(7):1024-33.

  13. 13

    Mulder GD, Patt LM, Sanders L, et al. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen, 2(4):259-69.

  14. 14

    Bishop JB, Phillips LG, Mustoe TA, et al. (1992). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg, 16(2):251-7.

  15. 15

    Miller TR, Wagner JD, Baack BR, et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4):252-9.

  16. 16

    Mokhtar J, Mohamad B, Haddad J, et al. (2026). The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J.

  17. 17

    Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. (2026). GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 18(9).

  18. 18

    Ogórek K, Nowak K, Wadych E, et al. (2025). Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules, 30(1).

  19. 19

    Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 19(7).

  20. 20

    Mayfield CK, Bolia IK, Feingold CL, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, 54(1):223-229.

  21. 21

    Li H, Toh PZ, Tan JY, et al. (2016). Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep, 6:37664.

  22. 22

    Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 56(8):1921-1935.

Regulatory & other sources

  1. S1

    PubChem, U.S. National Library of Medicine. Prezatide copper (CID 71587328) and glycyl-L-histidyl-L-lysine (CID 73587). Accessed Oct 2, 2026.

  2. S2

    U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (GHK-Cu entry). Accessed Oct 2, 2026.

  3. S3

    World Anti-Doping Agency (copy hosted by the International Testing Agency). World Anti-Doping Code International Standard: Prohibited List 2026 (S0, non-approved substances). Accessed Oct 2, 2026.